6:35 PM
 | 
Dec 15, 2011
 |  BC Extra  |  Clinical News

Rib-X's delafloxacin non-inferior to Zyvox, vancomycin in Phase IIb

Rib-X Pharmaceuticals Inc. (New Haven, Conn.) said delafloxacin met the primary endpoint of global cure rate at day 14 by demonstrating non-inferiority to both Zyvox linezolid and IV vancomycin...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >